Suppr超能文献

[精神分裂症阴性症状的药理学治疗方法]

[Pharmacologic approach to negative symptoms in schizophrenia].

作者信息

Jalenques I

机构信息

Service de Psychiatrie A, Centre Médico-Psychologique, Groupe Hospitalier St-Jacques, Clermont-Ferrand.

出版信息

Encephale. 1995 Jun;21 Spec No 3:35-40.

PMID:7628340
Abstract

Various pharmacologic agents have been reported to be effective in treating negative symptoms of schizophrenia. European schools of psychiatry and especially the French one assumed the opinion that part of negative symptoms of schizophrenia do respond to neuroleptics. In light of effects of reserpine and some phenothiazines on negative schizophrenia, various pharmacologic agents have been studied focusing on these properties. Various papers devoted to this question concluded that some drugs, particularly neuroleptics, can be considered as disinhibitors: phenothiazines (thiotixene, trifluoperazine, fluphenazine, pipotiazine), butyrophenones (trifluperidol, risperidone), diphenylbutylpiperidines (pimozide) and benzamides (sulpiride, amisulpiride). Major part of controlled studies concluded to the better efficacy of low doses of such drugs on negative symptoms, while high doses are almost inefficient. Some studies concluded in the activity of clozapine on negative symptoms of schizophrenic patients. To answer the question whether negative symptoms of schizophrenia are improved concomitantly or independently of improvement in positive symptoms or of decrease in extrapyramidal side effects and/or depressive symptoms, the authors prospectively followed up for 30 months, 13 DSM-IV resistant schizophrenics. Symptoms were assessed by means of 18 item Brief Psychiatric Rating Scale, Positive and Negative Syndrome Scale and Extrapyramidal Symptom Rating Scale (ESRS). Improvement in negative symptoms was significantly correlated to improvement in positive ones and to scores in ESRS. Many open studies concerning anti-depressants and other drugs have been published; however controlled studies are necessary to confirm these data.

摘要

据报道,多种药物制剂对治疗精神分裂症的阴性症状有效。欧洲的精神病学派,尤其是法国学派认为,精神分裂症的部分阴性症状确实对抗精神病药物有反应。鉴于利血平和某些吩噻嗪类药物对阴性精神分裂症的作用,人们对具有这些特性的多种药物制剂进行了研究。许多关于这个问题的论文得出结论,某些药物,特别是抗精神病药物,可以被视为去抑制药:吩噻嗪类(替沃噻吨、三氟拉嗪、氟奋乃静、哌泊噻嗪)、丁酰苯类(三氟哌多、利培酮)、二苯基丁基哌啶类(匹莫齐特)和苯甲酰胺类(舒必利、氨磺必利)。大部分对照研究得出结论,低剂量的这类药物对阴性症状疗效更好,而高剂量几乎无效。一些研究得出结论,氯氮平对精神分裂症患者的阴性症状有活性。为了回答精神分裂症的阴性症状改善是与阳性症状改善同时发生,还是独立于阳性症状改善、锥体外系副作用和/或抑郁症状的减轻,作者对13名DSM-IV难治性精神分裂症患者进行了为期30个月的前瞻性随访。症状通过18项简明精神病评定量表、阳性和阴性症状量表以及锥体外系症状评定量表(ESRS)进行评估。阴性症状的改善与阳性症状的改善以及ESRS评分显著相关。已经发表了许多关于抗抑郁药和其他药物的开放性研究;然而,需要对照研究来证实这些数据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验